highli
pathogen
avian
influenza
virus
current
circul
southeast
asia
may
acquir
potenti
caus
next
influenza
pandem
number
altern
approach
pursu
gener
crossprotect
dosespar
safe
effect
vaccin
tradit
vaccin
approach
ie
embryon
egggrown
immunogen
develop
replicationincompet
adenovir
vectorbas
adjuvantand
eggindepend
pandem
influenza
vaccin
strategi
potenti
altern
convent
eggderiv
vaccin
vaccin
strategi
interpandem
period
prime
popul
vaccin
offer
crossprotect
pandem
viru
perfect
match
pandem
vaccin
made
howev
manufactur
prepandem
pandem
vaccin
tradit
method
ie
embryon
chicken
egggrown
may
take
month
addit
tradit
influenza
vaccin
immunogen
requir
heighten
biosafeti
facil
billion
embryon
egg
manufactur
enough
vaccin
dose
immun
highrisk
individu
worldwid
baculovirusderiv
recombin
hemagglutinin
ha
protein
virus
elimin
need
egg
biosafeti
requir
costeffect
also
shown
poorli
immunogen
figur
altern
approach
gener
vaccin
seed
viru
without
need
high
contain
manufactur
facil
becam
possibl
advent
revers
genet
technolog
observ
delet
multibas
aminoacid
cleavag
site
ha
molecul
affect
antigen
thu
gener
candid
vaccin
strain
revers
genet
contain
modifi
ha
wildtyp
neuraminidas
viru
remain
six
gene
becam
possibl
first
us
food
drug
administrationapprov
egggrown
reassort
vaccin
develop
also
facilit
gener
coldadapt
viru
vaccin
figur
season
influenza
viru
aann
contain
modifi
ha
neuraminidas
gene
viru
attenu
enabl
limit
replic
specif
upper
airway
nasal
passag
howev
approach
still
reli
uninterrupt
suppli
embryon
egg
avian
influenza
virus
highli
lethal
chicken
ensur
avail
embryon
egg
vaccin
product
pose
major
challeng
note
current
worldwid
egggrown
influenza
vaccinemanufactur
capac
oper
full
capac
would
also
abl
meet
demand
address
issu
dosespar
strategi
investig
reduc
amount
antigen
requir
gener
robust
immun
respons
inclus
adjuv
altern
eggindepend
vaccin
strategi
outlin
figur
also
develop
high
degre
success
preclin
clinic
studi
name
mammalian
cellderiv
vaccin
viral
vector
recombin
protein
viruslik
particl
dna
vaccin
passiv
immun
cocktail
monoclon
antibodi
prefer
profil
effect
pandem
vaccin
safe
effect
popul
health
statu
immunogen
prefer
low
dose
one
administr
easili
inexpens
manufactur
effect
variant
pandem
influenza
virus
induc
humor
cellular
immun
respons
thermost
shelf
life
year
unadjuv
vaccin
meet
mani
characterist
addit
adjuv
adjuvantindepend
strategi
pursu
group
other
develop
replicationdefici
human
adenovir
vector
approach
pandem
vaccin
strategi
vector
approach
use
safe
effect
vaccin
strategi
preclin
clinic
studi
number
infecti
diseas
includ
human
immunodefici
viru
hepat
b
viru
measl
rabi
anthrax
ebola
sever
acut
respiratori
syndrom
corona
viru
sever
form
cancer
furthermor
advector
approach
shown
excel
safeti
profil
clinic
trial
strategi
elimin
need
embryon
egg
requir
viru
growth
well
need
enhanc
biosafeti
level
laboratori
vector
grown
high
titer
qualifi
cell
line
short
period
time
overcom
glycosyl
issu
lead
better
immunogen
immun
parenter
mucos
rout
lead
foreign
gene
express
without
insert
genom
host
genom
furthermor
vector
engag
innat
immun
respons
tolllik
receptordepend
tolllik
receptorindepend
pathway
target
dendrit
cell
macrophag
thu
requir
adjuv
engag
arm
immun
respons
hadvector
deliveri
approach
gener
humor
cellmedi
immun
target
diseas
use
approach
gener
effect
pandem
vaccin
logic
altern
tradit
eggderiv
vaccin
previous
shown
protect
lethal
challeng
antigen
distinct
strain
virus
mice
immun
express
ha
gene
ahong
absenc
detect
neutral
hemagglutin
antibodi
vaccin
gener
humor
immun
respons
antigen
similar
viru
well
tcell
respons
conserv
epitop
conserv
nearli
human
virus
isol
sinc
includ
human
virus
isol
c
smith
person
commun
find
indic
hadbas
prepandem
vaccin
confer
broader
protect
offer
stockpil
option
ideal
prepandem
pandem
influenza
vaccin
possess
abil
gener
robust
longlast
protect
immun
respons
small
amount
antigen
meet
global
demand
paper
assess
immun
respons
vaccin
use
suboptim
dose
immun
strategi
show
protect
challeng
antigen
similar
viru
provid
low
dose
vaccin
even
absenc
detect
antibodi
also
demonstr
vaccin
induc
longlast
protect
humor
cellmedi
immun
respons
least
month
postimmun
find
clearli
indic
eggand
adjuvantindepend
advectorbas
pandem
influenza
vaccin
strategi
confer
protect
antigen
distinct
strain
gener
longlast
protect
immun
viabl
altern
tradit
eggderiv
vaccin
previous
report
plaqueform
unit
pfu
vaccin
optim
dose
induct
protect
antibodi
respons
determin
hemagglutin
inhibit
hi
test
neutral
antibodi
induc
vaccin
mirror
hi
antibodi
titer
seen
figur
neutral
antibodi
titer
induc
vaccin
dose
pfu
respect
indic
protect
titer
howev
pfu
vaccin
dose
detect
serolog
respons
observ
nevertheless
mice
challeng
lethal
dose
antigen
similar
viru
ahong
hk
group
mice
protect
death
except
group
receiv
either
vaccin
dose
pfu
empti
vector
figur
howev
mice
immun
vaccin
dose
pfu
show
morbid
weight
loss
day
fulli
recov
wherea
mice
immun
vaccin
pfu
dose
exhibit
littl
weight
loss
figur
previous
shown
vaccin
induc
tcell
respons
confer
protect
death
even
absenc
neutral
antibodi
respons
antigen
distinct
viru
henc
protect
confer
vaccin
pfu
dose
may
due
cell
andor
nonneutr
antibodi
antibodydepend
cellmedi
cytotox
mechan
determin
vaccin
induc
durabl
protect
immun
mice
immun
intramuscularli
im
intranas
twice
week
apart
pfu
vaccin
im
empti
vector
bled
interv
week
postboost
assess
humor
immun
respons
hi
antibodi
titer
week
determin
hors
hi
assay
im
immun
respect
immun
respect
wherea
hi
antibodi
empti
vector
group
remain
background
level
figur
comparison
prechalleng
bleed
mice
receiv
booster
immun
week
prior
mice
receiv
booster
immun
week
prior
indic
neutral
antibodi
titer
remain
protect
level
shown
figur
mice
bled
week
postboost
vaccin
gener
neutral
antibodi
titer
im
immun
respect
wherea
mice
bled
week
postimmun
vaccin
gener
neutral
titer
im
immun
respect
analysi
epitop
specif
cell
indic
frequenc
tcell
respons
week
postboost
similar
level
induc
week
postboost
figur
frequenc
epitopespecif
cell
week
postboost
group
immun
im
rout
respect
week
postimmun
respect
group
signific
level
p
epitop
specif
cell
compar
empti
vector
control
group
nucleoprotein
epitopespecif
pentam
stain
level
remain
background
level
indic
anim
expos
influenza
virus
cours
studi
data
shown
follow
challeng
lethal
dose
viru
mice
immun
vaccin
protect
exhibit
littl
morbid
indic
weight
loss
figur
data
clearli
indic
vaccin
gener
longlast
humor
cellular
immun
respons
confer
complet
protect
lethal
challeng
even
month
postimmun
differ
observ
rout
immun
sinc
highli
pathogen
avian
influenza
report
bird
countri
report
human
infect
report
human
case
result
death
current
vaccin
season
influenza
protect
virul
strain
highli
pathogen
avian
influenza
thu
effect
vaccin
highli
pathogen
avian
influenza
urgent
public
health
prioriti
previous
found
pfu
optim
dose
gener
protect
immun
respons
determin
hi
titer
mice
receiv
pfu
vaccin
neutral
antibodi
hi
antibodi
level
detect
assay
still
complet
protect
suggest
protect
lethal
challeng
absenc
neutral
antibodi
level
detect
facilit
mechan
name
cellmedi
immun
nonneutr
nonhemagglutin
antibodi
possibl
antibodydepend
cellmedi
cytotox
vaccin
administ
im
rout
mucos
antibodi
play
role
protect
also
shown
earlier
although
nonneutr
antibodi
play
role
clearanc
antigen
similar
virus
protect
antigen
distinct
strain
influenza
virus
requir
cellmedi
immun
name
cytotox
lymphocyt
well
antibodydepend
cellmedi
cytotox
protect
clinic
trial
involv
tradit
vaccin
approach
suggest
antibodi
respons
gener
tradit
vaccin
human
tend
wane
detect
month
postimmun
detect
booster
immun
case
advector
vaccin
epitopespecif
cell
gener
hepat
c
persist
nonhuman
primat
least
month
postimmun
haddeliv
herp
simplex
viru
glycoprotein
b
induc
specif
antibodi
cell
vaccin
maintain
sever
month
similarli
antibodi
respons
antigen
simian
immunodefici
viru
deliv
detect
month
postimmun
wherea
tcellspecif
respons
detect
least
month
postimmun
mice
schwartz
et
al
recent
shown
protect
immun
respons
lethal
challeng
vaccin
vesicular
stomat
viru
vector
express
detect
least
month
postboost
mice
data
also
show
humor
cellmedi
immun
respons
induc
vaccin
detect
least
month
postimmun
mice
preexist
humor
immun
respons
influenza
aid
prevent
limit
infect
wherea
preexist
cellmedi
respons
aid
recoveri
shorten
durat
ill
humor
cellular
immun
respons
induc
advectorbas
vaccin
longlast
crossprotect
vaccin
potenti
confer
protect
drift
variant
mechan
hadvector
immun
due
preexposur
adenoviru
address
howev
shown
two
recent
clinic
trial
correl
immun
respons
antigen
preexist
vectorspecif
antibodi
exist
human
although
advectorbas
human
immunodefici
viru
vaccin
gener
slight
decreas
cellbas
immun
respons
subject
preexist
antibodi
compar
seroneg
group
decreas
minim
higher
antigen
dose
prepandem
vaccin
either
eggderiv
recombin
protein
express
baculoviru
shown
poor
elicit
robust
immun
respons
antigen
similar
virus
unless
adjuv
henc
prudent
consid
altern
strategi
develop
pandem
vaccin
given
current
manufactur
capac
constraint
depend
embryon
egg
therefor
hadvector
vaccin
strategi
viabl
option
stockpil
could
potenti
use
prepandem
pandem
vaccin
doserespons
studiessix
group
balbc
mice
jackson
laboratori
bar
harbor
anesthet
intraperiton
administr
avertin
sigma
st
loui
mo
g
bodi
weight
immun
im
thigh
decreas
log
concentr
vaccin
vector
express
ha
gene
ahong
start
pfu
empti
vector
four
week
later
mice
boost
concentr
empti
vector
sera
obtain
week
postboost
retroorbit
bleed
determin
haspecif
antibodi
respons
viru
microneutr
assay
hi
assay
use
hors
red
blood
cell
detect
ha
antibodi
mice
challeng
lethal
dose
ld
antigen
similar
influenza
viru
monitor
day
clinic
sign
weight
loss
indic
morbid
cdc
institut
anim
care
use
committe
iacuc
approv
procedur
involv
anim
experi
involv
conduct
biosafeti
level
contain
enhanc
requir
us
depart
agricultur
select
agent
program
longev
studiesthre
group
balbc
mice
mice
per
group
immun
im
anesthesia
pfu
empti
vector
thigh
pfu
light
anesthesia
co
ga
nostril
four
week
later
mice
boost
vaccin
rout
administr
sera
obtain
retroorbit
bleed
week
postboost
determin
antibodyspecif
respons
describ
follow
bleed
eight
week
challeng
three
separ
group
mice
immun
twice
im
pfu
im
pfu
empti
vector
comparison
mice
immun
week
sera
obtain
retroorbit
bleed
challeng
serolog
analysi
describ
six
mice
per
group
challeng
monitor
day
clinic
sign
weight
loss
spleen
harvest
remain
four
mice
determin
cellmedi
immun
respons
cellmedi
immun
responsesa
singlecel
suspens
splenocyt
obtain
four
individu
mice
subject
fluorescenceactiv
cell
sort
analysi
epitopicspecif
respons
k
specif
class
mhc
molecul
pentam
stain
brief
splenocyt
prepar
gentl
passag
tissu
steril
mesh
screen
creat
singlecel
suspens
pentam
stain
cell
resuspend
phosphatebuff
salin
bovin
serum
albumin
sodium
azid
stain
buffer
block
min
ice
fc
block
bd
bioscienc
san
diego
ca
follow
addit
either
pe
phycoerythrin
label
ha
iystvassl
np
tyqrtralv
epitopespecif
pentam
proimmun
springfield
va
antibodyconjug
apc
allophycocyanin
min
room
temperatur
event
collect
bd
bioscienc
facscalibur
flow
cytomet
data
analyz
use
cellquest
pro
softwar
pentam
use
neg
control
cell
stain
pentam
expos
infecti
viru
np
viral
peptid
serolog
responsessera
mice
subject
receptordestroy
enzym
vibrio
cholera
denka
seiken
tokyo
japan
overnight
destroy
nonspecif
serum
inhibitor
activ
presenc
hi
antibodi
determin
use
four
hemagglutin
unit
bpropiolactoneinactiv
viru
hors
red
blood
cell
neutral
antibodi
determin
use
viru
microneutr
assay
assess
abil
neutral
homolog
viru
prepar
pandem
number
vaccin
approach
current
investig
preclin
clinic
trial
approach
depict
one
six
circl
surround
core
describ
pandem
influenza
vaccin
factor
affect
outcom
success
vaccin
rang
dose
includ
doselimit
strategi
immun
schedul
formul
adjuv
immunostimulatori
compound
effort
meet
prefer
profil
effect
vaccin
rg
revers
genet
vsv
vesicular
stomat
viru
balbc
mice
immun
im
vari
dose
vaccin
start
pfu
twice
week
apart
indic
x
axi
empti
vector
group
includ
neg
control
four
week
postboost
sera
obtain
detect
neutral
solid
bar
hemagglutin
empti
bar
antibodi
viru
microneutr
assay
hi
assay
use
hors
red
blood
cell
respect
b
week
three
addit
group
naiv
mice
immun
schedul
immun
sera
obtain
week
postboost
six
group
mice
week
week
determin
neutral
antibodi
titer
viru
microneutr
assay
balbc
mice
immun
im
pfu
im
empti
vector
twice
week
apart
age
week
three
addit
group
mice
immun
schedul
immun
week
spleen
harvest
four
mice
group
week
postboost
pass
screen
obtain
singlecel
suspens
mous
splenocyt
resuspend
phosphatebuff
salin
bovin
serum
albumin
sodium
azid
stain
buffer
block
min
ice
fc
block
follow
pe
phycoerythrin
label
epitopespecif
pentam
antibodi
conjug
apc
allophycocyanin
analyz
flow
cytometri
tight
gate
around
tcell
popul
data
express
box
whisker
plot
interquartil
rang
p
empti
vector
twice
week
apart
age
addit
week
b
fortyeight
week
first
three
group
immun
three
addit
group
mice
immun
schedul
immun
group
mice
challeng
ld
ahong
monitor
clinic
sign
weight
loss
day
